Notably, bone alterations in these models occurred against the background of hyperphosphatemia [7,8,11,13] and significant changes in the circulating levels of FGF23, PTH [7,10,12,13], Dickkopf-1, and sclerostin [6,8,13]. The gene discussed is FGF23; the disease is hyperphosphatemia.